A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This open-label, single-arm, multicenter study will evaluate the efficacy and safety in
participants with metastatic melanoma who developed brain metastases. Participants may or may
not have received prior systemic treatment for metastatic melanoma [except treatment with
v-raf murine sarcoma viral oncogene homolog B (BRAF) or mitogen-activated protein kinase
(MEK) inhibitors]. Participants will receive oral doses of 960 mg vemurafenib twice daily
until disease progression, unacceptable toxicity or consent withdrawal.